ArticleCell cycle (Georgetown, Tex.)2011
Identification of dAven, a Drosophila melanogaster ortholog of the cell cycle regulator Aven.
Article in Cell cycle (Georgetown, Tex.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Mammalian RNA Decay Pathways Are Highly Specialized and Widely Linked to Translation.Molecular cell · 2020Article
- Altering the sex determination pathway in Drosophila fat body modifies sex-specific stress responses.American journal of physiology. Regulatory, integrative and comparative physiology · 2014Article
- Aven is dynamically regulated during Xenopus oocyte maturation and is required for oocyte survival.Cell death & disease · 2013Article
- Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.Cancer research · 2013Article
- Multiple functions of BCL-2 family proteins.Cold Spring Harbor perspectives in biology · 2013Review
- An Integrated Bioinformatics and Computational Biology Approach Identifies New BH3-Only Protein Candidates.The open biology journal · 2012Article
- Flying to a halt: Drosophila Aven arrests the cell cycle.Cell cycle (Georgetown, Tex.) · 2011Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Aven is a regulator of the DNA-damage response and G2/M cell cycle progression. Overexpression of Aven is associated with poor prognosis in patients with childhood acute lymphoblastic leukemia and acute myeloid leukemia, and altered intracellular Aven distribution is associated with infiltrating ductal carcinoma and papillary carcinoma breast cancer subtypes. Although Aven orthologs have been identified in most vertebrate species, no Aven gene has been reported in invertebrates. Here, we describe a Drosophila melanogaster open reading frame (ORF) that shares sequence and functional similarities with vertebrate Aven genes. The protein encoded by this ORF, which we named dAven, contains several domains that are highly conserved among Aven proteins of fish, amphibian, bird and mammalian origins. In flies, knockdown of dAven by RNA interference (RNAi) resulted in lethality when its expression was reduced either ubiquitously or in fat cells using Gal4 drivers. Animals undergoing moderate dAven knockdown in the fat body had smaller fat cells displaying condensed chromosomes and increased levels of the mitotic marker phosphorylated histone H3 (PHH3), suggesting that dAven was required for normal cell cycle progression in this tissue. Remarkably, expression of dAven in Xenopus egg extracts resulted in G2/M arrest that was comparable to that caused by human Aven. Taken together, these results suggest that, like its vertebrate counterparts, dAven plays a role in cell cycle regulation. Drosophila could be an excellent model for studying the function of Aven and identifying cellular factors that influence its activity, revealing information that may be relevant to human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.